

Loncastuximab



Included Products: Zynlonta (loncastuximab tesirine-lpyl)

Created: 07/08/2021

Revised: 07/08/2021

Reviewed: 07/08/2021

Updated: 10/06/2021

All Diagnoses

Initial Criteria		If yes	If no
1.	Is treatment being initiated by a hematologist/oncologist?	Continue to #2.	Do not approve.
2.	Is Zynlonta supported by the NCCN with a category 2A recommendation or higher for the requested use?	Continue to #3.	Do not approve.
3.	Is Monjuvi supported by the NCCN with a category 2A recommendation or higher for the requested use?	Continue to #4.	Continue to #5.
4.	Has Monjuvi been tried, or is there a medical reason Monjuvi cannot be used?	Continue to #5.	Deny, offer Monjuvi.
5.	Approve for 6 months.		
Renewal Criteria		If yes	If no
1.	Is there documentation of response since starting Zynlonta therapy?	Continue to #2.	Do not approve.
2.	Approve for 6 months		